Eskander Ramez N, Tewari Krishnansu S
Irvine Medical Center, University of California, Orange, California, USA.
Curr Opin Obstet Gynecol. 2014 Aug;26(4):314-21. doi: 10.1097/GCO.0000000000000042.
Patients with cervical cancer represent a vulnerable population with limited chemotherapeutic options. This year, two large trials focusing on detection/screening and treatment of advanced stage cervical cancer were featured in the opening plenary session of the American Society of Clinical Oncology Annual Meeting. As such, a review of the evolution of chemotherapy in the treatment of this disease is warranted.
Following the establishment of cisplatin as an effective single-agent regimen in patients with advanced stage, recurrent, or persistent cervical cancer, several platinum-containing combinations were studied. Ultimately, the adoption of cisplatin chemosensitizing radiation resulted in relative 'cisplatin resistance' and the concept of nonplatinum doublets emerged as an active area of investigation.
In an era of biologics, combined therapy with cytotoxic drugs and molecular targeted agents, as well as the use of nonplatinum doublets, represent an exciting area yet to be fully explored.
宫颈癌患者是化疗选择有限的弱势群体。今年，两项聚焦晚期宫颈癌检测/筛查及治疗的大型试验在美国临床肿瘤学会年会的开幕全体会议上备受关注。因此，有必要回顾一下该疾病化疗的发展历程。
在顺铂被确立为晚期、复发或持续性宫颈癌患者的有效单药治疗方案后，人们对几种含铂联合方案进行了研究。最终，顺铂增敏放疗的应用导致了相对的“顺铂耐药”，非铂双联方案的概念成为一个活跃的研究领域。
在生物制剂时代，细胞毒性药物与分子靶向药物的联合治疗以及非铂双联方案的应用，是一个令人兴奋但尚未得到充分探索的领域。
